search
Back to results

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Primary Purpose

Gastric Cancer, Cancer of the Stomach, Esophagogastric Junction

Status
Active
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
BMS-986213
Nivolumab
XELOX
FOLFOX
SOX
Sponsored by
Bristol-Myers Squibb
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastric Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Histologically- or cytologically-confirmed diagnosis of unresectable and either locally advanced, or metastatic gastric cancer or GEJ adenocarcinoma
  • No prior treatment with systemic treatment (including HER 2 inhibitors) given as primary therapy for unresectable and either locally advanced, or metastatic GC or GEJ adenocarcinoma
  • Tumor tissue must be provided for biomarker analyses

Exclusion Criteria:

  • Participants with HER2 positive status
  • Participants with known untreated central nervous system (CNS) metastases
  • Uncontrolled or significant cardiovascular disease

Other protocol defined inclusion/exclusion criteria could apply

Sites / Locations

  • Local Institution - 0049
  • Local Institution - 0064
  • Scripps Clinic
  • Local Institution - 0040
  • Hoag Memorial Hospital Presbyterian
  • Local Institution - 0041
  • Local Institution - 0077
  • Local Institution - 0056
  • Local Institution - 0062
  • Local Institution - 0050
  • Local Institution - 0054
  • Local Institution
  • Local Institution - 0052
  • Local Institution - 0010
  • Local Institution - 0009
  • Local Institution - 0011
  • Local Institution - 0078
  • Local Institution - 0027
  • Local Institution - 0007
  • Local Institution - 0003
  • Local Institution - 0029
  • Local Institution - 0005
  • Local Institution - 0028
  • Local Institution - 0090
  • Local Institution - 0089
  • Local Institution - 0091
  • Local Institution - 0092
  • Local Institution - 0024
  • Local Institution - 0063
  • Local Institution - 0070
  • Local Institution - 0055
  • Local Institution - 0095
  • Local Institution
  • Local Institution - 0080
  • Local Institution - 0001
  • Local Institution - 0079
  • Local Institution - 0031
  • Local Institution - 0030
  • Local Institution - 0047
  • Local Institution - 0073
  • Local Institution - 0045
  • Local Institution - 0071
  • Local Institution - 0043
  • Local Institution - 0072
  • Local Institution - 0046
  • Local Institution - 0083
  • Local Institution - 0082
  • Local Institution - 0017
  • Local Institution - 0081
  • Local Institution - 0014
  • Local Institution - 0018
  • Medizinische Hochschule Hannover
  • Local Institution - 0013
  • Local Institution - 0015
  • Local Institution - 0016
  • IRCCS Istituto Nazionale Tumori Milano
  • Local Institution - 0020
  • Local Institution - 0021
  • Local Institution - 0088
  • Local Institution - 0086
  • Local Institution - 0087
  • Local Institution - 0093
  • Local Institution - 0067
  • Local Institution - 0038
  • Local Institution - 0058
  • Local Institution - 0099
  • Local Institution - 0098
  • Local Institution - 0061
  • Local Institution - 0059
  • Local Institution - 0057
  • Local Institution - 0060
  • Local Institution - 0075
  • Local Institution - 0035
  • Local Institution - 0032
  • Local Institution - 0036
  • Local Institution - 0034
  • Local Institution - 0069
  • Local Institution - 0033

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

BMS-986213 + investigator's choice chemotherapy

Nivolumab + investigator's choice chemotherapy

Arm Description

BMS-986213 + XELOX or BMS-986213 + FOLFOX or BMS-986213 + SOX

Nivolumab + XELOX or Nivolumab + FOLFOX or Nivolumab + SOX

Outcomes

Primary Outcome Measures

BICR-Assessed Objective Response Rate (ORR) in Randomized LAG-3 Positive (>=1 %) Participants
The number of LAG-3 Positive (>=1%) participants with a Best Overall Response (BOR) of confirmed Complete Response (CR) or Partial Response (PR) divided by the number of randomized LAG-3 positive (>=1%) participants in each arm; recorded between randomization date and the date of objectively documented progression [per RECISIT 1.1], death due to any cause, or date of subsequent anticancer therapy, whichever occurs first. CR= Disappearance of all target lesions PR= At least a 30% decrease in the sum of diameters of target lesions

Secondary Outcome Measures

Objective Response Rate (ORR)
Objective response rate (ORR) based on Blinded Independent Central Review (BICR) and Investigator assessments is defined as the number of participants with a Best Overall Response (BOR) of confirmed Complete Response (CR) or Partial Response (PR) divided by the number of randomized participants in each arm; recorded between randomization date and the date of objectively documented progression [per RECISIT 1.1], death due to any cause, or date of subsequent anticancer therapy, whichever occurs first.
Duration of Response (DOR)
Duration of Response (DOR) based on Blinded Independent Central Review (BICR) and investigator is defined as the time between the date of first documented response (complete response or partial response) and the date of the first disease progression, per RECIST 1.1, or death due to any cause, or date of subsequent anticancer therapy, whichever occurs first.
Overall Survival (OS)
Overall Survival (OS) is defined as the time between the date of randomization and the date of death due to any cause. For those without documentation of death, OS will be censored on the last date the participant was known to be alive.
Progression-Free Survival (PFS)
Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR) and Investigator is defined as the time between the date of randomization and the first date of documented progression, or death due to any cause, or date of subsequent anticancer therapy, whichever occurs first. Participants who die without a reported prior progression (and die without start of subsequent therapy) will be considered to have progressed on the date of death.
Number of Participants With Adverse Events (AEs)
Number of participants with any grade adverse events (AEs), serious adverse events (SAE), and adverse events leading to discontinuation using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v 5.0) to assess the overall safety and tolerability of BMS-986213 in combination with chemotherapy vs. Nivolumab in combination with chemotherapy.
Number of Deaths
Number of deaths in each arm to assess the overall safety and tolerability of BMS-986213 in combination with chemotherapy vs. Nivolumab in combination with chemotherapy.
Number of Participants With Laboratory Abnormalities in Specific Liver Tests
Number of participants with laboratory abnormalities in specific liver tests based on US conventional units to assess the overall safety and tolerability of BMS-986213 in combination with chemotherapy vs. Nivolumab in combination with chemotherapy. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized: ALT or AST > 3 x ULN, > 5 x ULN, > 10 x ULN and > 20 x ULN Total bilirubin > 2 x ULN ALP > 1.5 x ULN Concurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 1.5 x ULN Concurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 1.5 x ULN Concurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN Concurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
Number of participants with laboratory abnormalities in specific thyroid tests based on US conventional units. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized: TSH value > ULN and with baseline TSH value <= ULN with at least one FT3/FT4 test value < LLN within 2-week window after the abnormal TSH test with all FT3/FT4 test values >= LLN within 2-week window after the abnormal TSH test with FT3/FT4 missing within 2-week window after the abnormal TSH test. TSH < LLN and with baseline TSH value >= LLN with at least one FT3/FT4 test value > ULN within 2-week window after the abnormal TSH test with all FT3/FT4 test values <= ULN within 2-week window after the abnormal TSH test with FT3/FT4 missing within 2-week window after the abnormal TSH test

Full Information

First Posted
September 6, 2018
Last Updated
October 3, 2023
Sponsor
Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT03662659
Brief Title
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Official Title
A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (Anti-LAG-3) and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-Line Treatment in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 16, 2018 (Actual)
Primary Completion Date
August 27, 2020 (Actual)
Study Completion Date
December 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bristol-Myers Squibb

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine the efficacy and safety of investigational drug relatlimab plus nivolumab in combination with chemotherapy in participants with unresectable, untreated, locally advanced or metastatic gastric or GEJ cancer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Cancer, Cancer of the Stomach, Esophagogastric Junction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
274 (Actual)

8. Arms, Groups, and Interventions

Arm Title
BMS-986213 + investigator's choice chemotherapy
Arm Type
Experimental
Arm Description
BMS-986213 + XELOX or BMS-986213 + FOLFOX or BMS-986213 + SOX
Arm Title
Nivolumab + investigator's choice chemotherapy
Arm Type
Experimental
Arm Description
Nivolumab + XELOX or Nivolumab + FOLFOX or Nivolumab + SOX
Intervention Type
Biological
Intervention Name(s)
BMS-986213
Intervention Description
Relatlimab + Nivolumab specified dose on specified days
Intervention Type
Biological
Intervention Name(s)
Nivolumab
Other Intervention Name(s)
Opdivo, BMS-936558
Intervention Description
Specified dose on specified days
Intervention Type
Drug
Intervention Name(s)
XELOX
Intervention Description
Oxaliplatin + capecitabine
Intervention Type
Drug
Intervention Name(s)
FOLFOX
Intervention Description
Oxaliplatin + leucovorin + fluorouracil
Intervention Type
Drug
Intervention Name(s)
SOX
Intervention Description
Oxaliplatin + tegafur/gimeracil/oteracil potassium
Primary Outcome Measure Information:
Title
BICR-Assessed Objective Response Rate (ORR) in Randomized LAG-3 Positive (>=1 %) Participants
Description
The number of LAG-3 Positive (>=1%) participants with a Best Overall Response (BOR) of confirmed Complete Response (CR) or Partial Response (PR) divided by the number of randomized LAG-3 positive (>=1%) participants in each arm; recorded between randomization date and the date of objectively documented progression [per RECISIT 1.1], death due to any cause, or date of subsequent anticancer therapy, whichever occurs first. CR= Disappearance of all target lesions PR= At least a 30% decrease in the sum of diameters of target lesions
Time Frame
Up to 25 months
Secondary Outcome Measure Information:
Title
Objective Response Rate (ORR)
Description
Objective response rate (ORR) based on Blinded Independent Central Review (BICR) and Investigator assessments is defined as the number of participants with a Best Overall Response (BOR) of confirmed Complete Response (CR) or Partial Response (PR) divided by the number of randomized participants in each arm; recorded between randomization date and the date of objectively documented progression [per RECISIT 1.1], death due to any cause, or date of subsequent anticancer therapy, whichever occurs first.
Time Frame
Up to 25 months
Title
Duration of Response (DOR)
Description
Duration of Response (DOR) based on Blinded Independent Central Review (BICR) and investigator is defined as the time between the date of first documented response (complete response or partial response) and the date of the first disease progression, per RECIST 1.1, or death due to any cause, or date of subsequent anticancer therapy, whichever occurs first.
Time Frame
Up to 25 months
Title
Overall Survival (OS)
Description
Overall Survival (OS) is defined as the time between the date of randomization and the date of death due to any cause. For those without documentation of death, OS will be censored on the last date the participant was known to be alive.
Time Frame
Up to 25 months
Title
Progression-Free Survival (PFS)
Description
Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR) and Investigator is defined as the time between the date of randomization and the first date of documented progression, or death due to any cause, or date of subsequent anticancer therapy, whichever occurs first. Participants who die without a reported prior progression (and die without start of subsequent therapy) will be considered to have progressed on the date of death.
Time Frame
Up to 25 months
Title
Number of Participants With Adverse Events (AEs)
Description
Number of participants with any grade adverse events (AEs), serious adverse events (SAE), and adverse events leading to discontinuation using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v 5.0) to assess the overall safety and tolerability of BMS-986213 in combination with chemotherapy vs. Nivolumab in combination with chemotherapy.
Time Frame
From first dose to 30 days post last dose (Up to 23 months)
Title
Number of Deaths
Description
Number of deaths in each arm to assess the overall safety and tolerability of BMS-986213 in combination with chemotherapy vs. Nivolumab in combination with chemotherapy.
Time Frame
Up to 25 months
Title
Number of Participants With Laboratory Abnormalities in Specific Liver Tests
Description
Number of participants with laboratory abnormalities in specific liver tests based on US conventional units to assess the overall safety and tolerability of BMS-986213 in combination with chemotherapy vs. Nivolumab in combination with chemotherapy. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized: ALT or AST > 3 x ULN, > 5 x ULN, > 10 x ULN and > 20 x ULN Total bilirubin > 2 x ULN ALP > 1.5 x ULN Concurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 1.5 x ULN Concurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 1.5 x ULN Concurrent (within 1 day) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN Concurrent (within 30 days) ALT or AST > 3 x ULN and total bilirubin > 2 x ULN
Time Frame
From first dose to up to 30 days post last dose (Up to 23 months)
Title
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
Description
Number of participants with laboratory abnormalities in specific thyroid tests based on US conventional units. The number of participants with the following laboratory abnormalities from on-treatment evaluations will be summarized: TSH value > ULN and with baseline TSH value <= ULN with at least one FT3/FT4 test value < LLN within 2-week window after the abnormal TSH test with all FT3/FT4 test values >= LLN within 2-week window after the abnormal TSH test with FT3/FT4 missing within 2-week window after the abnormal TSH test. TSH < LLN and with baseline TSH value >= LLN with at least one FT3/FT4 test value > ULN within 2-week window after the abnormal TSH test with all FT3/FT4 test values <= ULN within 2-week window after the abnormal TSH test with FT3/FT4 missing within 2-week window after the abnormal TSH test
Time Frame
From first dose to up to 30 days post last dose (Up to 23 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 Histologically- or cytologically-confirmed diagnosis of unresectable and either locally advanced, or metastatic gastric cancer or GEJ adenocarcinoma No prior treatment with systemic treatment (including HER 2 inhibitors) given as primary therapy for unresectable and either locally advanced, or metastatic GC or GEJ adenocarcinoma Tumor tissue must be provided for biomarker analyses Exclusion Criteria: Participants with HER2 positive status Participants with known untreated central nervous system (CNS) metastases Uncontrolled or significant cardiovascular disease Other protocol defined inclusion/exclusion criteria could apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
Local Institution - 0049
City
Clovis
State/Province
California
ZIP/Postal Code
93611
Country
United States
Facility Name
Local Institution - 0064
City
Duarte
State/Province
California
ZIP/Postal Code
91010-3012
Country
United States
Facility Name
Scripps Clinic
City
La Jolla
State/Province
California
ZIP/Postal Code
92037
Country
United States
Facility Name
Local Institution - 0040
City
Los Angeles
State/Province
California
ZIP/Postal Code
90033
Country
United States
Facility Name
Hoag Memorial Hospital Presbyterian
City
Newport Beach
State/Province
California
ZIP/Postal Code
92663
Country
United States
Facility Name
Local Institution - 0041
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Local Institution - 0077
City
Santa Monica
State/Province
California
ZIP/Postal Code
90404
Country
United States
Facility Name
Local Institution - 0056
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
Local Institution - 0062
City
New Haven
State/Province
Connecticut
ZIP/Postal Code
06520
Country
United States
Facility Name
Local Institution - 0050
City
Hackensack
State/Province
New Jersey
ZIP/Postal Code
07601
Country
United States
Facility Name
Local Institution - 0054
City
Dallas
State/Province
Texas
ZIP/Postal Code
75216
Country
United States
Facility Name
Local Institution
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23230
Country
United States
Facility Name
Local Institution - 0052
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
Facility Name
Local Institution - 0010
City
Ciudad Autónoma de Buenos Aires
State/Province
Buenos Aires
ZIP/Postal Code
1280
Country
Argentina
Facility Name
Local Institution - 0009
City
Buenos Aires
State/Province
Ciudad Autónoma De Buenos Aires
ZIP/Postal Code
C1093AAS
Country
Argentina
Facility Name
Local Institution - 0011
City
San Miguel de Tucumán
State/Province
Tucumán
ZIP/Postal Code
T4000IAK
Country
Argentina
Facility Name
Local Institution - 0078
City
Caba
ZIP/Postal Code
1426
Country
Argentina
Facility Name
Local Institution - 0027
City
Westmead
State/Province
New South Wales
ZIP/Postal Code
2145
Country
Australia
Facility Name
Local Institution - 0007
City
Herston
State/Province
Queensland
ZIP/Postal Code
4029
Country
Australia
Facility Name
Local Institution - 0003
City
Heidelberg
State/Province
Victoria
ZIP/Postal Code
3084
Country
Australia
Facility Name
Local Institution - 0029
City
Malvern
State/Province
Victoria
ZIP/Postal Code
3144
Country
Australia
Facility Name
Local Institution - 0005
City
Murdoch
State/Province
Western Australia
ZIP/Postal Code
6150
Country
Australia
Facility Name
Local Institution - 0028
City
Bedford Park
ZIP/Postal Code
5024
Country
Australia
Facility Name
Local Institution - 0090
City
Graz
ZIP/Postal Code
8036
Country
Austria
Facility Name
Local Institution - 0089
City
Wien
ZIP/Postal Code
1090
Country
Austria
Facility Name
Local Institution - 0091
City
Bruxelles
ZIP/Postal Code
1200
Country
Belgium
Facility Name
Local Institution - 0092
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Local Institution - 0024
City
Kelowna
State/Province
British Columbia
ZIP/Postal Code
V1Y 5L3
Country
Canada
Facility Name
Local Institution - 0063
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H 2Y9
Country
Canada
Facility Name
Local Institution - 0070
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Facility Name
Local Institution - 0055
City
Trois-Rivieres
State/Province
Quebec
ZIP/Postal Code
G8Z 3R9
Country
Canada
Facility Name
Local Institution - 0095
City
Quebec
ZIP/Postal Code
G1R 2J6
Country
Canada
Facility Name
Local Institution
City
Rancagua
State/Province
L.g.bernardoohiggins
Country
Chile
Facility Name
Local Institution - 0080
City
Santiago
State/Province
Metropolitana
Country
Chile
Facility Name
Local Institution - 0001
City
Vina del Mar
State/Province
Valparaiso
ZIP/Postal Code
2520598
Country
Chile
Facility Name
Local Institution - 0079
City
Santiago
ZIP/Postal Code
0
Country
Chile
Facility Name
Local Institution - 0031
City
Brno
ZIP/Postal Code
656 53
Country
Czechia
Facility Name
Local Institution - 0030
City
Olomouc
ZIP/Postal Code
779 00
Country
Czechia
Facility Name
Local Institution - 0047
City
Avignon Cedex 9
ZIP/Postal Code
84918
Country
France
Facility Name
Local Institution - 0073
City
Besancon Cedex
ZIP/Postal Code
25030
Country
France
Facility Name
Local Institution - 0045
City
Dijon
ZIP/Postal Code
21000
Country
France
Facility Name
Local Institution - 0071
City
Montpellier
ZIP/Postal Code
34090
Country
France
Facility Name
Local Institution - 0043
City
Paris
ZIP/Postal Code
75010
Country
France
Facility Name
Local Institution - 0072
City
Paris
ZIP/Postal Code
75012
Country
France
Facility Name
Local Institution - 0046
City
Rouen Cedex
ZIP/Postal Code
76031
Country
France
Facility Name
Local Institution - 0083
City
Cologne
ZIP/Postal Code
50937
Country
Germany
Facility Name
Local Institution - 0082
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Facility Name
Local Institution - 0017
City
Essen
ZIP/Postal Code
45136
Country
Germany
Facility Name
Local Institution - 0081
City
Essen
ZIP/Postal Code
45147
Country
Germany
Facility Name
Local Institution - 0014
City
Frankfurt
ZIP/Postal Code
60488
Country
Germany
Facility Name
Local Institution - 0018
City
Hamburg
ZIP/Postal Code
20249
Country
Germany
Facility Name
Medizinische Hochschule Hannover
City
Hannover
ZIP/Postal Code
30625
Country
Germany
Facility Name
Local Institution - 0013
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
Facility Name
Local Institution - 0015
City
Mannheim
ZIP/Postal Code
68167
Country
Germany
Facility Name
Local Institution - 0016
City
Marburg
ZIP/Postal Code
35043
Country
Germany
Facility Name
IRCCS Istituto Nazionale Tumori Milano
City
Milano
ZIP/Postal Code
20133
Country
Italy
Facility Name
Local Institution - 0020
City
Milan
ZIP/Postal Code
20132
Country
Italy
Facility Name
Local Institution - 0021
City
Roma
ZIP/Postal Code
00168
Country
Italy
Facility Name
Local Institution - 0088
City
Bergen
ZIP/Postal Code
5021
Country
Norway
Facility Name
Local Institution - 0086
City
Oslo
ZIP/Postal Code
0450
Country
Norway
Facility Name
Local Institution - 0087
City
Trondheim
ZIP/Postal Code
7030
Country
Norway
Facility Name
Local Institution - 0093
City
Warszawa
ZIP/Postal Code
02-034
Country
Poland
Facility Name
Local Institution - 0067
City
San Juan
ZIP/Postal Code
00927
Country
Puerto Rico
Facility Name
Local Institution - 0038
City
Singapore
ZIP/Postal Code
168583
Country
Singapore
Facility Name
Local Institution - 0058
City
Madrid
State/Province
M
ZIP/Postal Code
28046
Country
Spain
Facility Name
Local Institution - 0099
City
Badajoz
ZIP/Postal Code
06080
Country
Spain
Facility Name
Local Institution - 0098
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Local Institution - 0061
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Local Institution - 0059
City
Bilbao
ZIP/Postal Code
48013
Country
Spain
Facility Name
Local Institution - 0057
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Facility Name
Local Institution - 0060
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
Facility Name
Local Institution - 0075
City
Manchester
State/Province
Greater Manchester
ZIP/Postal Code
M20 4BX
Country
United Kingdom
Facility Name
Local Institution - 0035
City
Nottingham
State/Province
Nottinghamshire
ZIP/Postal Code
NG5 1PB
Country
United Kingdom
Facility Name
Local Institution - 0032
City
Coventry
State/Province
West Midlands
ZIP/Postal Code
CV2 2DX
Country
United Kingdom
Facility Name
Local Institution - 0036
City
Lancaster
ZIP/Postal Code
LA1 4RP
Country
United Kingdom
Facility Name
Local Institution - 0034
City
London
ZIP/Postal Code
SE1 9RT
Country
United Kingdom
Facility Name
Local Institution - 0069
City
Northwood
ZIP/Postal Code
HA6 2RN
Country
United Kingdom
Facility Name
Local Institution - 0033
City
Southampton
ZIP/Postal Code
SO16 6YD
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
35623069
Citation
Chang X, Ge X, Zhang Y, Xue X. The current management and biomarkers of immunotherapy in advanced gastric cancer. Medicine (Baltimore). 2022 May 27;101(21):e29304. doi: 10.1097/MD.0000000000029304.
Results Reference
derived
Links:
URL
https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Description
BMS Clinical Trial Information
URL
https://www.bmsstudyconnect.com/s/US/English/USenHome
Description
BMS Clinical Trial Patient Recruiting

Learn more about this trial

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

We'll reach out to this number within 24 hrs